{"name":"Tanabe Pharma America, Inc.","slug":"tanabe-pharma-america-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"MT-7117 high dose","genericName":"MT-7117 high dose","slug":"mt-7117-high-dose","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"MT-7117","genericName":"MT-7117","slug":"mt-7117","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"MT-7117 low dose","genericName":"MT-7117 low dose","slug":"mt-7117-low-dose","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"}]}],"pipeline":[{"name":"MT-7117 high dose","genericName":"MT-7117 high dose","slug":"mt-7117-high-dose","phase":"phase_3","mechanism":"MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"MT-7117","genericName":"MT-7117","slug":"mt-7117","phase":"phase_3","mechanism":"MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"MT-7117 low dose","genericName":"MT-7117 low dose","slug":"mt-7117-low-dose","phase":"phase_3","mechanism":"MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxORTNtQnpiVGUtcXlSREZ4bW9QNkg5WVQtdlZydVVCLU5zYmVTSjlUWkNBMlVsUG9iWlpxdUdwVDloZTd4U3otQ1VkWW1SLVl5YldWZTVULUhuaGdlMHlzRmZJM0dLUDc4ZXNKQXFuZjE0VGV3RmpXeEVUQXM5N2EyY2piWllvNFc4X3V3LXVzYnM2S0ozc1FqLUxGS3NHZnNJbnBwWDdIbHEwU01Xb24yT05OUjRnQi1XRmZTT2tjVTREWHQ4QlM3NllHc3NENEZ2Nmk4X0NvdU5zYlVrMlJ3akR4LUxFWWVZSWxpS1RaYUpjTG52cUxaaHFzOHVFbktNRTU0aE0wS3FRcVNSQTlhamR1bDBjcHF2TnVGTlNwQ1NYZDNCSVhYcw?oc=5","date":"2026-04-01","type":"pipeline","source":"Block Island Times","summary":"Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi - Block Island Times","headline":"Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRmpwbG1rVElEd1NmMUlDMXA5Z2hSQ2hoZlBqSU50VFltc1ZESjhnNkdCbk0xaFpqaFNMRUJlbUlKSGFjaVJORE9UcUtpZ2g4bGZXOTZvZjdscThFZ1dMWFdJOUpzY19zdnZMRVVJVXVHQXhJNDZabTJZaGd1Y1lIYmtUZUF4b0VybWVzbXlvbUJIOW1Rc2tsc2luOVhob0ppbE1Pd3hxUWhLQW5oTDctcEFRRlYycWhMaUtXcndiZDA?oc=5","date":"2026-04-01","type":"pipeline","source":"Business Wire","summary":"Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire","headline":"Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOdy1LRXFSMW9HdlNnZ085dGZMZlhJQmtyb09vM0VNNHJfSG5MSGMxY0ItbFBqdGNSUnMzOG5tMTVlUW1UbWFzbmlHM1dVQ0ZWREd0OC16U3kzUWFJMDhBUUVUcEhFNUJPRlFUYW16S2RXenhzMERMN3JCMm5laTdkMVdReGRDZDNCblctOUNpOGxTcGx6bFdBMGE3eUZlWkE0eW0xRnRaenE5QXZRQ0dSVlBmYUdsM1lBaUw1MmZXakZqbzVtcmJxQ2oyaUQ0WDlUSDNYQ0dkX1NNT3hRcE9GY3Q5YnlocVJYaTE1cXB2VExjLVgzSFp4LWs1b1daTmVfNXFiQUNya1llTzRpenYyT3o0WFp3TzVuNFF5MklKTUplUQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Newswire Canada","summary":"Finding Strength in Shared Stories: Tanabe Pharma Canada Introduces New Book for the Canadian ALS Community - 'Letters to ALS: Our Journeys to Hope' - Newswire Canada","headline":"Finding Strength in Shared Stories: Tanabe Pharma Canada Introduces New Book for the Canadian ALS Community - 'Letters t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPT1RsRlhLTFplNDVHdHVPR1lIVHB5X3c5djZFNURFRlV1TGRzNGUtdFFoMHd3Q19LRTFlTTFpYkdZaFF4LWZYX3FsNDQ1TEpTd04xQndJeG9DVmYtLWZMT00wNUhXQTBMczBZWmFRYmdOeDFvRE9yaXZDY1dud2Z3QjQwSGtBaUF3cXF2ZjN0T3U2MHoyXzNIZGN4SWQ0VmM5X0VZUnlobTlxa0JlV2pjSThnbTlCdkNfbnVmNTRxZkMxSzQ2WFhtVmVrRktOdTR4dkZSNnVhUXFZZTdmVWtuYmhoOFZ3Ui11?oc=5","date":"2026-03-05","type":"pipeline","source":"PR Newswire","summary":"Tanabe Pharma America to Highlight Research in ALS at 2026 MDA Clinical and Scientific Conference - PR Newswire","headline":"Tanabe Pharma America to Highlight Research in ALS at 2026 MDA Clinical and Scientific Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQOXZIT3dSbkRxY3lrT1JybVd4TFNLSlBqUGR5akJKU3daVzk4N1pjR3dCT003UURnYl9VeWhmY19VZHRfVHJNTGhWTWl6UTR5cGpvdE9sdmZmUGJwRFNILXNmSUM1Q21JQjRHdWJqUXFLVnNOUWtMQmlQenhpd09ZSUtSUW40Z2FsYkJpZTRELVR4bzFVR2ZmM0laMDRUdW02emJVYkUxWUxMbFJPSVdXSmY1enZmbndjS0VjYw?oc=5","date":"2026-01-20","type":"regulatory","source":"Fierce Biotech","summary":"Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark - Fierce Biotech","headline":"Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQcWR1THQ5di1TMWpFRHhPUkN5V2pjZzZsNkYtMndxeHphdzNid3lCc0d5QVVkR25Ra1g1MFdlbV9xSTNiQVZfb1JlbGN6U2hJWTdMdmNTc3BRcWk2UVBiWHZYdi04ck1ITFV4eFpxUUU1dnRrZndtQlEtTHVQQ1RWcE03VU5IMEM5YkxLMFNCZzVMbk9oeTl2RW9KcHBZZ2pXZVRKZ1c0cWl5RFJHaXFjQnZ0TQ?oc=5","date":"2026-01-20","type":"trial","source":"Clinical Trials Arena","summary":"Tanabe Pharma’s dersimelagon hits success in Phase III EPP and XLP trial - Clinical Trials Arena","headline":"Tanabe Pharma’s dersimelagon hits success in Phase III EPP and XLP trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOLXp5enVNcU9aQll2cU54RTRJYnVFZzM2U28xUlB3VTBFUndDdS15M3RSTl9oSmg5NF9MRUFXRFRpenM3WS1CMHhSSEJCSW5TT1ZjN1FHZUxWMnFJRVNJN0d5RjN0Q2hJUFNZSEdmZDA0bXVua0Y3bF9nZDJtOGlWVjI1bmpiR091enBnQjlsajR5WEpQRk8tMVp5c1c0N0VyeFA3ZmZ5dGwtdzdCZ09sekF3Y3RCNkxpVmJCcVI2dkg?oc=5","date":"2026-01-02","type":"deal","source":"NJ.com","summary":"Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal - NJ.com","headline":"Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9BV3h2N2ZjNlpXRFlpNnZNTTR0Wm1VU091ejgtcE1zWmJKX3paTm42SWg0cXRpWFZocEpjUUs2ZXBHdGtMbzNNRkZtem9DYTg5NG5Cc1U3Q09ieldQek15N25HMlBlUnVtVmlCTVQ2YlZZYWN0d0pz?oc=5","date":"2025-12-23","type":"deal","source":"NJBIZ","summary":"Shionogi to buy Jersey City pharma for $2.5B - NJBIZ","headline":"Shionogi to buy Jersey City pharma for $2.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZ2NyOW1zOTQ4dXRiWEtmeTlCUmVsSHN5Mi1uRFZiSlp4UjBzLTI5MFlSQjMzNlNIVF9OVkRsNFpSTlJrdnp4a0ktZUpwRWhnZHMtb3BQbGxZYnVhakZzeklrLWRjSExRbExsOUJiV0F6bWJRa1BLRXlxdGJ4R3YyZXpOX0wtajNjdG1mblpLUGRBTV93ZVNJUENhVjZ2c2RLc3I3Q081MDZ1RS03T3NJZjNUbVctQQ?oc=5","date":"2025-12-09","type":"pipeline","source":"bloomberg.com","summary":"Bain Is Said to Mull Selling Tanabe Pharma’s Non-Japanese Assets - bloomberg.com","headline":"Bain Is Said to Mull Selling Tanabe Pharma’s Non-Japanese Assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUVVJY1piSDhnS282S1h5eEV3QVdueWFDbkU1MEMtRHFSay1jZDdNNkNoZFJZUTNiZWk5eWwzaWlDaDJrczNTVzlqV3NZSnZJZ0QyaXJ0aHpxSWpUVEFXLWRteWRKV2cyODV3ckc1N0lwSXFLeklvcDVSNG9KY2lVM01EcHkxT2xvNmcwRkE5R0dYUzBkc0pucWlBSjJOcnBGZmlWcWgxTXVMSUJxT3QwWWg0N2dWazVT?oc=5","date":"2025-12-01","type":"pipeline","source":"PR Newswire","summary":"Mitsubishi Tanabe Pharma America is Now Tanabe Pharma America - PR Newswire","headline":"Mitsubishi Tanabe Pharma America is Now Tanabe Pharma America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQVGFUOVhJTEYwblcwa2tnTHJIcVdWbGxCTzlvSG93b0VIVnVGd1NtZnhIdUw0ZTZTWGxFc19ZSmg5ODB1QzZoQkxFVmd0VkUyUHlpZ25XZzlHNmRDeFBuWjJoeVBYaDhLWmNTYjVSbjZhRWdhUFp4MWdZaWFGaHJiR0NDWUtrQS1INXQxSTQwU0gwSm5HZjVNVkVzRGRFMUlJZFc0b0FmbDJ6cVZZeHpRM1FONmtkbDlocGhwb0V1TUkyS3ZuWEE?oc=5","date":"2025-12-01","type":"deal","source":"Fierce Pharma","summary":"Tanabe Pharma shifts gears for Bain-backed future, dropping Mitsubishi moniker after $3.3B deal - Fierce Pharma","headline":"Tanabe Pharma shifts gears for Bain-backed future, dropping Mitsubishi moniker after $3.3B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNclcwTmtpNlFLekpQZktDTEY5R05OYVNJdXU4OGNMSkYyZ0htMlhfMDlpVVk5RktnQW9FQ0ZqUGhVVTlmREVFQlpDNmdjU29TMl9PMWZjVk10US02LWMxZWJKUDNyTk45ZUlsSDBsMmt4cnRlTGJNYWhwaU5FQTlObjREZFZtdU0?oc=5","date":"2025-10-13","type":"pipeline","source":"ALS News Today","summary":"My Journey to Accept Living With ALS - ALS News Today","headline":"My Journey to Accept Living With ALS","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}